“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Monday, August 25, 2025

Lexicon Pharmaceuticals


Lexicon Pharmaceuticals – Product Catalog (A–Z)

A

  • Adexor (pipeline candidate) → unknown codename – discontinued program → Cardiovascular indication (legacy pipeline) → No marketed dose

B

  • BX471 (legacy) → chemokine receptor 1 antagonist → Inflammatory/immune disorders (discontinued) → Oral (investigational; no marketed strengths)

C

  • Carisbamate (LX6171, legacy) → antiepileptic agent → Partial-onset seizures (discontinued after Phase III) → Oral tablets (trial use only)

D

  • Dexpramipexole (KNS-760704, legacy licensed to Knopp) → R-enantiomer of pramipexole → ALS, eosinophilic disorders (under study) → Oral capsule (phase II/III trials, 150–300 mg bid studied)

  • Dorzagliatin (LX4211, dual SGLT1/2 inhibitor, partnered/legacy) → sotagliflozin (see below) – see S section

E

  • Epalrestat analogue (LX-series, early) → Aldose reductase inhibitor candidate → Diabetic complications → Not marketed

I

  • Indiplon (legacy) → sedative-hypnotic, GABA-A modulator → Insomnia (discontinued; FDA non-approval) → Oral tablet, studied at 10–20 mg hs

L

  • LX1031 → tryptophan hydroxylase inhibitor → Irritable bowel syndrome (IBS) – serotonin modulation → Oral (phase II)

  • LX1032 (telotristat etiprate, later Xermelo) → tryptophan hydroxylase inhibitor → Carcinoid syndrome diarrhea (licensed to Lexicon/partner) → Oral tablets 250 mg tid (marketed as Xermelo)

  • LX1606 (alternate name for telotristat) → Same as above

  • LX2761 → intestinal SGLT1 inhibitor → Type 1 & 2 diabetes, GI glucose absorption modulation → Oral, phase II (low systemic absorption)

  • LX4211 (sotagliflozin) → dual SGLT1 & SGLT2 inhibitor → Type 1 diabetes, heart failure, CKD → Oral tablets 200 mg, 400 mg once daily studied (now marketed as Inpefa)

  • LX9211 → AP2-associated kinase 1 (AAK1) inhibitor → Neuropathic pain (diabetic neuropathy) → Oral, phase II positive results

I (marketed)

  • Inpefa → sotagliflozin → Heart failure with preserved/reduced ejection fraction, diabetic CKD → Tablets 200 mg, 400 mg daily

T

  • Telotristat (Xermelo) → tryptophan hydroxylase inhibitor → Carcinoid syndrome diarrhea in metastatic neuroendocrine tumors → Oral 250 mg tid

X

  • Xermelo → telotristat ethyl → Carcinoid syndrome diarrhea → 250 mg tablets tid




on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)